Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2388393 | 0.85 | AR (0.44) | ARIDO1TDO2GPR119 | |
| SCHEMBL2391797 | 0.85 | AR (0.73) | AR | |
| SCHEMBL16223901 | 0.84 | AR (0.40) | ARCHRM2AKR1B1 | |
| SCHEMBL16223900 | 0.84 | AR (0.40) | ARCHRM2AKR1B1 | |
| SCHEMBL2390677 | 0.84 | AR (0.40) | ARCHRM2AKR1B1 | |
| SCHEMBL2393424 | 0.84 | AR (0.54) | AR | |
| SCHEMBL2391445 | 0.83 | AR (0.54) | AR | |
| SCHEMBL3275489 | 0.81 | AR (0.54) | ARCHRM2AKR1B1 | |
| SCHEMBL2393269 | 0.80 | AR (0.74) | AR | |
| SCHEMBL2392204 | 0.80 | AR (0.53) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2098507-B1 | Cyclic amine compound as androgen receptor modulator | TAKEDA PHARMACEUTICAL (JP) | 2014-11-12 | — | — | EP | claimed |
| US-8013008-B2 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-06 | — | — | US | claimed |
| US-20100087506-A1 | CYCLIC AMINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | claimed |
| EP-2098507-A1 | CYCLIC AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-09 | — | — | EP | claimed |
| EP-2098507-B1 | Cyclic amine compound as androgen receptor modulator | TAKEDA PHARMACEUTICAL (JP) | 2014-11-12 | — | — | EP | disclosed |
| EP-2098507-B1 | Cyclic amine compound as androgen receptor modulator | TAKEDA PHARMACEUTICAL (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-8013008-B2 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-06 | — | — | US | disclosed |
| US-8013008-B2 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-06 | — | — | US | disclosed |
| US-8013008-B2 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20100087506-A1 | CYCLIC AMINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| US-20100087506-A1 | CYCLIC AMINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| US-20100087506-A1 | CYCLIC AMINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-2098507-A1 | CYCLIC AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-09 | — | — | EP | disclosed |
| EP-2098507-A1 | CYCLIC AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087506-A1 | CYCLIC AMINE COMPOUND | AR, FSHR, NR5A1 | AR 1/4885IDO1 2960/4885TDO2 2062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.